175 related articles for article (PubMed ID: 35183090)
1. A physical mechanism of heterogeneity and micro-metastasis in stem cells, cancer cells, and cancer stem cells.
Yu C; Liu Q; Wang J
J Chem Phys; 2022 Feb; 156(7):075103. PubMed ID: 35183090
[TBL] [Abstract][Full Text] [Related]
2. Landscape perspectives of tumor, EMT, and development.
Yu C; Liu Q; Chen C; Yu J; Wang J
Phys Biol; 2019 Jul; 16(5):051003. PubMed ID: 31067516
[TBL] [Abstract][Full Text] [Related]
3. Cancer stem cell heterogeneity: origin and new perspectives on CSC targeting.
Eun K; Ham SW; Kim H
BMB Rep; 2017 Mar; 50(3):117-125. PubMed ID: 27998397
[TBL] [Abstract][Full Text] [Related]
4. A physical mechanism of cancer heterogeneity.
Chen C; Wang J
Sci Rep; 2016 Feb; 6():20679. PubMed ID: 26854017
[TBL] [Abstract][Full Text] [Related]
5. Distinct epigenetic regulation of tumor suppressor genes in putative cancer stem cells of solid tumors.
Yasuda H; Soejima K; Watanabe H; Kawada I; Nakachi I; Yoda S; Nakayama S; Satomi R; Ikemura S; Terai H; Sato T; Suzuki S; Matsuzaki Y; Naoki K; Ishizaka A
Int J Oncol; 2010 Dec; 37(6):1537-46. PubMed ID: 21042723
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic approach of Cancer stem cells (CSCs) in gastric adenocarcinoma; DNA methyltransferases enzymes in cancer targeted therapy.
Norollahi SE; Mansour-Ghanaei F; Joukar F; Ghadarjani S; Mojtahedi K; Gharaei Nejad K; Hemmati H; Gharibpoor F; Khaksar R; Samadani AA
Biomed Pharmacother; 2019 Jul; 115():108958. PubMed ID: 31075731
[TBL] [Abstract][Full Text] [Related]
7. Epigenetic alterations involved in cancer stem cell reprogramming.
Muñoz P; Iliou MS; Esteller M
Mol Oncol; 2012 Dec; 6(6):620-36. PubMed ID: 23141800
[TBL] [Abstract][Full Text] [Related]
8. [Epigenetics in cancer stem cells].
Xu LF; Zhang J; Tian ZQ; Wu YZ
Yi Chuan; 2013 Sep; 35(9):1049-57. PubMed ID: 24400477
[TBL] [Abstract][Full Text] [Related]
9. Stem cell programs in cancer initiation, progression, and therapy resistance.
Huang T; Song X; Xu D; Tiek D; Goenka A; Wu B; Sastry N; Hu B; Cheng SY
Theranostics; 2020; 10(19):8721-8743. PubMed ID: 32754274
[TBL] [Abstract][Full Text] [Related]
10. Basal/HER2 breast carcinomas: integrating molecular taxonomy with cancer stem cell dynamics to predict primary resistance to trastuzumab (Herceptin).
Martin-Castillo B; Oliveras-Ferraros C; Vazquez-Martin A; Cufí S; Moreno JM; Corominas-Faja B; Urruticoechea A; Martín ÁG; López-Bonet E; Menendez JA
Cell Cycle; 2013 Jan; 12(2):225-45. PubMed ID: 23255137
[TBL] [Abstract][Full Text] [Related]
11. Evolving Strategies for Therapeutically Targeting Cancer Stem Cells.
Talukdar S; Emdad L; Das SK; Sarkar D; Fisher PB
Adv Cancer Res; 2016; 131():159-91. PubMed ID: 27451127
[TBL] [Abstract][Full Text] [Related]
12. DNMT1 Inhibition Reprograms Pancreatic Cancer Stem Cells via Upregulation of the miR-17-92 Cluster.
Zagorac S; Alcala S; Fernandez Bayon G; Bou Kheir T; Schoenhals M; González-Neira A; Fernandez Fraga M; Aicher A; Heeschen C; Sainz B
Cancer Res; 2016 Aug; 76(15):4546-58. PubMed ID: 27261509
[TBL] [Abstract][Full Text] [Related]
13. Epigenetics and Cancer Stem Cells: Unleashing, Hijacking, and Restricting Cellular Plasticity.
Wainwright EN; Scaffidi P
Trends Cancer; 2017 May; 3(5):372-386. PubMed ID: 28718414
[TBL] [Abstract][Full Text] [Related]
14. BORIS up-regulates OCT4 via histone methylation to promote cancer stem cell-like properties in human liver cancer cells.
Liu Q; Chen K; Liu Z; Huang Y; Zhao R; Wei L; Yu X; He J; Liu J; Qi J; Qin Y; Li B
Cancer Lett; 2017 Sep; 403():165-174. PubMed ID: 28645561
[TBL] [Abstract][Full Text] [Related]
15. Understanding cancer stem cell heterogeneity and plasticity.
Tang DG
Cell Res; 2012 Mar; 22(3):457-72. PubMed ID: 22357481
[TBL] [Abstract][Full Text] [Related]
16. Molecular Mechanisms Underlying the Functions of Cellular Markers Associated with the Phenotype of Cancer Stem Cells.
Alvarado-Ortiz E; Sarabia-Sánchez MÁ; García-Carrancá A
Curr Stem Cell Res Ther; 2019; 14(5):405-420. PubMed ID: 30147013
[TBL] [Abstract][Full Text] [Related]
17. Understanding cell signaling in cancer stem cells for targeted therapy - can phosphoproteomics help to reveal the secrets?
Gruber W; Scheidt T; Aberger F; Huber CG
Cell Commun Signal; 2017 Mar; 15(1):12. PubMed ID: 28356110
[TBL] [Abstract][Full Text] [Related]
18. Activation of Matrix Hyaluronan-Mediated CD44 Signaling, Epigenetic Regulation and Chemoresistance in Head and Neck Cancer Stem Cells.
Bourguignon LYW; Earle C; Shiina M
Int J Mol Sci; 2017 Aug; 18(9):. PubMed ID: 28837080
[TBL] [Abstract][Full Text] [Related]
19. Breast cancer stem cells, heterogeneity, targeting therapies and therapeutic implications.
Zeng X; Liu C; Yao J; Wan H; Wan G; Li Y; Chen N
Pharmacol Res; 2021 Jan; 163():105320. PubMed ID: 33271295
[TBL] [Abstract][Full Text] [Related]
20. Human hepatic cancer stem cells are characterized by common stemness traits and diverse oncogenic pathways.
Marquardt JU; Raggi C; Andersen JB; Seo D; Avital I; Geller D; Lee YH; Kitade M; Holczbauer A; Gillen MC; Conner EA; Factor VM; Thorgeirsson SS
Hepatology; 2011 Sep; 54(3):1031-42. PubMed ID: 21618577
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
